A new trading day began on Friday, with Mineralys Therapeutics Inc (NASDAQ: MLYS) stock price up 4.31% from the previous day of trading, before settling in for the closing price of $11.83. MLYS’s price has ranged from $7.29 to $16.91 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -85.50%. With a float of $23.55 million, this company’s outstanding shares have now reached $49.76 million.
Let’s determine the extent of company efficiency that accounts for 28 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mineralys Therapeutics Inc (MLYS) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Mineralys Therapeutics Inc is 52.68%, while institutional ownership is 49.46%. The most recent insider transaction that took place on Nov 11 ’24, was worth 75,398. In this transaction Chief Medical Officer of this company sold 5,026 shares at a rate of $15.00, taking the stock ownership to the 140,991 shares. Before that another transaction happened on Nov 11 ’24, when Company’s Officer proposed sale 5,026 for $15.00, making the entire transaction worth $75,398.
Mineralys Therapeutics Inc (MLYS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -85.50% per share during the next fiscal year.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Here are Mineralys Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.27, a number that is poised to hit -1.08 in the next quarter and is forecasted to reach -3.85 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
Looking closely at Mineralys Therapeutics Inc (NASDAQ: MLYS), its last 5-days average volume was 0.19 million, which is a jump from its year-to-date volume of 0.18 million. As of the previous 9 days, the stock’s Stochastic %D was 28.25%. Additionally, its Average True Range was 0.84.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 56.37%, which indicates a significant increase from 43.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.13% in the past 14 days, which was lower than the 72.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.10, while its 200-day Moving Average is $12.62. However, in the short run, Mineralys Therapeutics Inc’s stock first resistance to watch stands at $12.71. Second resistance stands at $13.08. The third major resistance level sits at $13.66. If the price goes on to break the first support level at $11.76, it is likely to go to the next support level at $11.18. Now, if the price goes above the second support level, the third support stands at $10.81.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
With a market capitalization of 640.63 million, the company has a total of 49,769K Shares Outstanding. Currently, annual sales are 0 K while annual income is -71,900 K. The company’s previous quarter sales were 0 K while its latest quarter income was -56,340 K.
